© 2024 WXPR
Play Live Radio
Next Up:
0:00 0:00
Available On Air Stations
0000017b-185c-d2e5-a37b-5cff92510000Wisconsin State and Local Government Sources: Wisconsin Department of Health Services: COVID-19 (Coronavirus Disease 2019)Oneida County Health DepartmentVilas County Health DepartmentLincoln County Health DepartmentMarathon County Health Department Langlade County Health DepartmentWestern Upper Peninsula Health DepartmentForest County Health DepartmentFederal Government Sources:Centers for Disease Control (CDC)Risk Assessment PageSituation Summary PageState Department Travel AdvisoriesWorld Health Organization (WHO)WHO Question and Answer Page

FDA Withdraws Emergency Use Authorization For Hydroxychloroquine

A bottle of hydroxychloroquine tablets in Texas City, Texas. The Food and Drug Administration has rescinded its emergency use authorization for the drug.
David J. Phillip
A bottle of hydroxychloroquine tablets in Texas City, Texas. The Food and Drug Administration has rescinded its emergency use authorization for the drug.

The U.S. Food and Drug Administration todaywithdrew a special status known as emergency use authorization for the drugs chloroquine and hydroxychloroquine.

Emergency use authorization is designed to facilitate the availability of drugs needed during public health emergencies. It allows unapproved medical products or unapproved uses of approved medical products to be used in such emergencies.

President Trump was an early and vocal champion of the drugs, and even declared in May that he was taking the drugs to prevent COVID-19.

Hydroxychloroquine and chloroquine were initially designed as anti-malarial drugs and later shown to be useful in treating certain autoimmune disorders. Early on in the pandemic, some researchers thought the drugs might be useful in treating COVID-19. Laboratory tests showed hydroxychloroquine interfered with the ability of the coronavirus that causes COVID-19 to enter cells. There were also hints from the use of the drugs in patients that they might be helpful. The FDA granted the emergency use authorization in March.

But those early positive results came from small studies that did not stand up well to scientific scrutiny. Larger, more carefully designed studies failed to show a benefit.

"It is no longer reasonable to believe that oral formulations of [hydroxychloroquine] and [chloroquine] may be effective in treating COVID-19, nor is it reasonable to believe that the known and potential benefits of these products outweigh their known and potential risks," said FDA chief scientist Denise M. Hinton put it in theletter explaining the agency's decision.

The FDA decision does not affect the use of the drugs in approved clinical trials.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

Joe Palca is a science correspondent for NPR. Since joining NPR in 1992, Palca has covered a range of science topics — everything from biomedical research to astronomy. He is currently focused on the eponymous series, "Joe's Big Idea." Stories in the series explore the minds and motivations of scientists and inventors. Palca is also the founder of NPR Scicommers – A science communication collective.
Up North Updates
* indicates required